{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:15:39Z","timestamp":1786986939629,"version":"build-2736575974"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100010412","name":"Global Risk Institute in Financial Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.clml.2024.08.003","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T22:04:56Z","timestamp":1723500296000},"page":"124-134.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1016","volume":"25","author":[{"given":"Jing Christine","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa","family":"Biran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandhya","family":"Nair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8942-2888","authenticated-orcid":false,"given":"Keqin","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5882-5388","authenticated-orcid":false,"given":"Eric","family":"Ammann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Renaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colleen","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilok","family":"Parekh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.clml.2024.08.003_bib0001","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.08.003_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020407","article-title":"Multiple myeloma: available therapies and causes of drug resistance","volume":"12","author":"Pinto","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clml.2024.08.003_bib0003","article-title":"Multiple myeloma: an overview of management","volume":"13","author":"Bird","year":"2019","journal-title":"Palliat Care Soc Pract"},{"issue":"25","key":"10.1016\/j.clml.2024.08.003_bib0004","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.08.003_bib0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.08.003_bib0006","unstructured":"BLENREP (belantamab mafodotin-blmf). Prescribing information. NC, USA: GlaxoSmithKline. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/761158s000lbl.pdf. Accessed: March 1, 2024."},{"key":"10.1016\/j.clml.2024.08.003_sbref0007","series-title":"Prescribing information","year":"2024"},{"issue":"Suppl 15","key":"10.1016\/j.clml.2024.08.003_bib0008","doi-asserted-by":"crossref","first-page":"8045","DOI":"10.1200\/JCO.2021.39.15_suppl.8045","article-title":"Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed\/refractory multiple myeloma (RRMM)","volume":"39","author":"Martin","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.08.003_bib0009","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1016\/j.clinthera.2021.09.013","article-title":"Treatment patterns and outcomes in triple-class exposed patients with relapsed and refractory multiple myeloma: findings from the multinational ITEMISE study","volume":"43","author":"Dhanasiri","year":"2021","journal-title":"Clin Ther"},{"issue":"9","key":"10.1016\/j.clml.2024.08.003_bib0010","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"issue":"Suppl 15","key":"10.1016\/j.clml.2024.08.003_bib0011","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1200\/JCO.2020.38.15_suppl.8525","article-title":"KarMMa-RW: a study of real-world treatment patterns in heavily pretreated patients with relapsed and refractory multiple myeloma (RRMM) and comparison of outcomes to KarMMa","volume":"38","author":"Jagannath","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.08.003_bib0012","doi-asserted-by":"crossref","first-page":"e449","DOI":"10.1016\/j.clml.2020.12.023","article-title":"Trends in early mortality from multiple myeloma: a population-based analysis","volume":"21","author":"Kumar","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"10.1016\/j.clml.2024.08.003_bib0013","doi-asserted-by":"crossref","first-page":"503","DOI":"10.2217\/fon-2020-1003","article-title":"Real-world treatment patterns, healthcare use and costs in triple-class exposed relapsed and refractory multiple myeloma patients in the USA","volume":"17","author":"Madduri","year":"2021","journal-title":"Future Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.08.003_bib0014","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.08.003_bib0015","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ctrv.2018.09.001","article-title":"Drug resistance in multiple myeloma","volume":"70","author":"Robak","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.clml.2024.08.003_bib0016","article-title":"CAR-T cell therapy in multiple myeloma: current limitations and potential strategies","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clml.2024.08.003_bib0017","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1177\/10781552231154809","article-title":"Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed\/refractory multiple myeloma","volume":"29","author":"Granger","year":"2023","journal-title":"J Oncol Pharm Pract"},{"issue":"9","key":"10.1016\/j.clml.2024.08.003_bib0018","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2024.08.003_sbref0019","series-title":"Prescribing information","year":"2023"},{"key":"10.1016\/j.clml.2024.08.003_sbref0020","series-title":"Summary of product characteristics","year":"2023"},{"key":"10.1016\/j.clml.2024.08.003_sbref0021","series-title":"Prescribing information","year":"2023"},{"key":"10.1016\/j.clml.2024.08.003_sbref0022","series-title":"Summary of product characteristics","year":"2023"},{"key":"10.1016\/j.clml.2024.08.003_bib0023","series-title":"Presented at: The 2023 American Society of Clinical Oncology (ASCO) Annual Meeting; June 2\u20136","article-title":"Pivotal phase 2 MonumenTAL-1 results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, for relapsed\/refractory multiple myeloma","author":"Schinke","year":"2023"},{"issue":"8","key":"10.1016\/j.clml.2024.08.003_bib0024","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2024.08.003_bib0025","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Phase 1\/2 results from MonumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.08.003_bib0026","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.clml.2024.08.003_bib0027","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2217\/cer-2022-0045","article-title":"Indirect treatment comparison of idecabtagene vicleucel versus conventional care in triple-class exposed multiple myeloma","volume":"11","author":"Shah","year":"2022","journal-title":"J Comp Eff Res"},{"issue":"9","key":"10.1016\/j.clml.2024.08.003_bib0028","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.clml.2022.04.025","volume":"22","author":"Weisel","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.08.003_bib0029","doi-asserted-by":"crossref","unstructured":"Ma X, Long L, Moon S, Adamson BJS, Baxi SS. Comparison of population characteristics in real-world clinical oncology databases in the US: flatiron health, SEER, and NPCR. Preprint. medRxiv preprint. 2023; doi:10.1101\/2020.03.16.20037143. Accessed: March 1, 2024.","DOI":"10.1101\/2020.03.16.20037143"},{"issue":"6","key":"10.1016\/j.clml.2024.08.003_bib0030","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2022-0186","article-title":"Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed\/refractory multiple myeloma","volume":"12","author":"Krishnan","year":"2023","journal-title":"J Comp Eff Res"},{"issue":"25","key":"10.1016\/j.clml.2024.08.003_bib0031","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"1","key":"10.1016\/j.clml.2024.08.003_bib0032","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/jha2.312","article-title":"Comparative effectiveness of ciltacabtagene autoleucel in CARTITUDE-1 versus physician's choice of therapy in the Flatiron Health multiple myeloma cohort registry for the treatment of patients with relapsed or refractory multiple myeloma","volume":"3","author":"Martin","year":"2022","journal-title":"EJHaem"},{"issue":"11","key":"10.1016\/j.clml.2024.08.003_bib0033","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.08.003_bib0034","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11899-020-00568-3","article-title":"Extramedullary disease in multiple myeloma","volume":"15","author":"Jagosky","year":"2020","journal-title":"Curr Hematol Malig Rep"},{"issue":"6","key":"10.1016\/j.clml.2024.08.003_bib0035","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"issue":"11","key":"10.1016\/j.clml.2024.08.003_bib0036","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1634\/theoncologist.2016-0104","article-title":"Analysis of real-world data on overall survival in multiple myeloma patients with\u2265 3 prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD), or double refractory to a PI and an IMiD","volume":"21","author":"Usmani","year":"2016","journal-title":"Oncologist"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024002957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T05:59:30Z","timestamp":1738043970000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024002957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S2152265024002957"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed\/Refractory Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}